BRCA1 targets G2/M cell cycle proteins for ubiquitination and proteasomal degradation

Oncogene

Volumn 32, Issue 42, 2013, Pages 5005-5016

  Shabbeer, S ^a,b   Omer, D ^c   Berneman, D ^c   Weitzman, O ^c   Alpaugh, A ^a   Pietraszkiewicz, A ^a   Metsuyanim, S ^c   Shainskaya, A ^d   Papa, M Z ^c   Yarden, R I ^a,b,c  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c SHEBA MEDICAL CENTER   (Israel)

^d WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

BRCA1; Cdc25; Cyclin B; G2 M cell cycle checkpoint; Proteasome; Ubiquitination

Indexed keywords

BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; BRCA1 PROTEIN; CDC25C PROTEIN; COMPLEMENTARY DNA; CYCLIN B; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN; PROTEIN MAD2; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; ENZYME ACTIVITY; G2 PHASE CELL CYCLE CHECKPOINT; GENOMIC INSTABILITY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; PROTEIN SYNTHESIS; RING FINGER MOTIF; UBIQUITINATION;

BRCA1 PROTEIN; CDC25 PHOSPHATASES; CELL DIVISION; CYCLIN B; G2 PHASE; GENE KNOCKDOWN TECHNIQUES; GENOMIC INSTABILITY; HUMANS; LEUPEPTINS; MCF-7 CELLS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PROTEIN INTERACTION DOMAINS AND MOTIFS; RING FINGER DOMAINS; UBIQUITIN-CONJUGATING ENZYMES; UBIQUITINATION;

EID: 84886089987     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.522     Document Type: Article

References (53)

1. Yarden RI, Papa MZ. BRCA1 at the crossroad of multiple cellular pathways: approaches for therapeutic interventions. Mol Cancer Ther 2006; 5: 1396-1404. (Pubitemid 44070475)
2. Lorick KL, Jensen JP, Fang S, Ong AM, Hatakeyama S, Weissman AM. RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc Natl Acad Sci USA 1999; 96: 11364-11369. (Pubitemid 29487386)
3. Mallery DL, Vandenberg CJ, Hiom K. Activation of the E3 ligase function of the BRCA1/BARD1 complex by polyubiquitin chains. Embo J 2002; 21: 6755-6762. (Pubitemid 36014547)
4. Xia Y, Pao GM, Chen HW, Verma IM, Hunter T. Enhancement of BRCA1 E3 ubiquitin ligase activity through direct interaction with the BARD1 protein. J Biol Chem 2003; 278: 5255-5263. (Pubitemid 36801039)
5. Yu X, Chini CC, He M, Mer G, Chen J. The BRCT domain is a phospho-protein binding domain. Science 2003; 302: 639-642. (Pubitemid 37310919)
6. Ruffner H, Joazeiro CA, Hemmati D, Hunter T, Verma IM. Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. Proc Natl Acad Sci USA 2001; 98: 5134-5139. (Pubitemid 32397095)
7. Ohta T, Sato K, Wu W. The BRCA1 ubiquitin ligase and homologous recombination repair. FEBS Lett 2011; 585: 2836-2844.
8. Kim H, Huang J, Chen J. CCDC98 is a BRCA1-BRCT domain-binding protein involved in the DNA damage response. Nat Struct Mol Biol 2007; 14: 710-715. (Pubitemid 47220062)
9. Wang B, Matsuoka S, Ballif BA, Zhang D, Smogorzewska A, Gygi SP et al. Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. Science 2007; 316: 1194-1198. (Pubitemid 46877482)
10. Sobhian B, Shao G, Lilli DR, Culhane AC, Moreau LA, Xia B et al. RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites. Science 2007; 316: 1198-1202. (Pubitemid 46877483)
11. Starita LM, Machida Y, Sankaran S, Elias JE, Griffin K, Schlegel BP et al. BRCA1-dependent ubiquitination of gamma-tubulin regulates centrosome number. Mol Cell Biol 2004; 24: 8457-8466. (Pubitemid 39245068)
12. Eakin CM, Maccoss MJ, Finney GL, Klevit RE. Estrogen receptor alpha is a putative substrate for the BRCA1 ubiquitin ligase. Proc Natl Acad Sci USA 2007; 104: 5794-5799. (Pubitemid 47175613)
13. Zhu Q, Pao GM, Huynh AM, Suh H, Tonnu N, Nederlof PM et al. BRCA1 tumour suppression occurs via heterochromatin-mediated silencing. Nature 2011; 477: 179-184.
14. Wu-Baer F, Lagrazon K, Yuan W, Baer R. The BRCA1/BARD1 heterodimer assembles polyubiquitin chains through an unconventional linkage involving lysine residue K6 of ubiquitin. J Biol Chem 2003; 278: 34743-34746. (Pubitemid 37102231)
15. Yu X, Fu S, Lai M, Baer R, Chen J. BRCA1 ubiquitinates its phosphorylationdependent binding partner CtIP. Genes Dev 2006; 20: 1721-1726. (Pubitemid 43992880)
16. Sato K, Hayami R, Wu W, Nishikawa T, Nishikawa H, Okuda Y et al. Nucleophosmin/B23 is a candidate substrate for the BRCA1-BARD1 ubiquitin ligase. J Biol Chem 2004; 279: 30919-30922. (Pubitemid 39037748)
17. Wu W, Nishikawa H, Hayami R, Sato K, Honda A, Aratani S et al. BRCA1 ubiquitinates RPB8 in response to DNA damage. Cancer Res 2007; 67: 951-958.
18. Starita LM, Horwitz AA, Keogh MC, Ishioka C, Parvin JD, Chiba N. BRCA1/BARD1 ubiquitinate phosphorylated RNA polymerase II. J Biol Chem 2005; 280: 24498-24505. (Pubitemid 40934535)
19. Horwitz AA, Affar el B, Heine GF, Shi Y, Parvin JD. A mechanism for transcriptional repression dependent on the BRCA1 E3 ubiquitin ligase. Proc Natl Acad Sci USA 2007; 104: 6614-6619. (Pubitemid 47175549)
20. Poole AJ, Li Y, Kim Y, Lin SC, Lee WH, Lee EY. Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 2006; 314: 1467-1470. (Pubitemid 44871955)
21. Calvo V, Beato M. BRCA1 counteracts progesterone action by ubiquitination leading to progesterone receptor degradation and epigenetic silencing of target promoters. Cancer Res 2011; 71: 3422-3431.
22. Yarden RI, Pardo-Reoyo S, Sgagias M, Cowan KH, Brody LC. BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage. Nat Genet 2002; 30: 285-289.
23. Yarden RI, Metsuyanim S, Pickholtz I, Shabbeer S, Tellio H, Papa MZ. BRCA1-dependent Chk1 phosphorylation triggers partial chromatin disassociation of phosphorylated Chk1 and facilitates S-phase cell cycle arrest. Int J Biochem Cell Biol 2012; 44: 1761-1769.
24. Hershko A. Mechanisms and regulation of the degradation of cyclin B. Philos Trans R Soc Lond B Biol Sci 1999; 354: 1571-1575(discussion 5-6).
25. Acquaviva C, Pines J. The anaphase-promoting complex/cyclosome: APC/C. J Cell Sci 2006; 119(Part 12): 2401-2404. (Pubitemid 44070421)
26. Chen F, Zhang Z, Bower J, Lu Y, Leonard SS, Ding M et al. Arsenite-induced Cdc25C degradation is through the KEN-box and ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 2002; 99: 1990-1995. (Pubitemid 34169002)
27. Pfleger CM, Kirschner MW. The KEN box: an APC recognition signal distinct from the D box targeted by Cdh1. Genes Dev 2000; 14: 655-665. (Pubitemid 30176820)
28. Yan Y, Spieker RS, Kim M, Stoeger SM, Cowan KH. BRCA1-mediated G2/M cell cycle arrest requires ERK1/2 kinase activation. Oncogene 2005; 24: 3285-3296. (Pubitemid 40695110)
29. Aprelikova OPA, Fang B, Koller BH, Liu ET. BRCA1 is a selective co-activator of 14-3-3 sigma gene transcription in mouse embryonic stem cells. J Biol Chem 2001; 276: 25647-25650.
30. Au WW, Henderson BR. The BRCA1 RING and BRCT domains cooperate in targeting BRCA1 to ionizing radiation-induced nuclear foci. J Biol Chem 2005; 280: 6993-7001. (Pubitemid 40341255)
31. Yu X, Chen J. DNA damage-induced cell cycle checkpoint control requires CtIP, a phosphorylation-dependent binding partner of BRCA1 C-terminal domains. Mol Cell Biol 2004; 24: 9478-9486. (Pubitemid 39391684)
32. Xu B, O'Donnell AH, Kim ST, Kastan MB. Phosphorylation of serine 1387 in Brca1 is specifically required for the Atm-mediated S-phase checkpoint after ionizing irradiation. Cancer Res 2002; 62: 4588-4591.
33. Wu-Baer F, Ludwig T, Baer R. The UBXN1 protein associates with autoubiquitinated forms of the BRCA1 tumor suppressor and inhibits its enzymatic function. Mol Cell Biol 2011; 30: 2787-2798.
34. Christensen DE, Brzovic PS, Klevit RE. E2-BRCA1 RING interactions dictate synthesis of mono-or specific polyubiquitin chain linkages. Nat Struct Mol Biol 2007; 14: 941-948. (Pubitemid 47525175)
35. Brandeis M, Hunt T. The proteolysis of mitotic cyclins in mammalian cells persists from the end of mitosis until the onset of S phase. Embo J 1996; 15: 5280-5289. (Pubitemid 26336211)
36. Homer HA, McDougall A, Levasseur M, Murdoch AP, Herbert M. Mad2 is required for inhibiting securin and cyclin B degradation following spindle depolymerisation in meiosis I mouse oocytes. Reproduction 2005; 130: 829-843. (Pubitemid 41830093)
37. Wang RH, Yu H, Deng CX. A requirement for breast-cancer-associated gene 1 (BRCA1) in the spindle checkpoint. Proc Natl Acad Sci USA 2004; 101: 17108-17113. (Pubitemid 39627782)
38. Stegmeier F, Rape M, Draviam VM, Nalepa G, Sowa ME, Ang XL et al. Anaphase initiation is regulated by antagonistic ubiquitination and deubiquitination activities. Nature 2007; 446: 876-881.
39. Innocente SA, Abrahamson JL, Cogswell JP, Lee JM. p53 regulates a G2 checkpoint through cyclin B1. Proc Natl Acad Sci USA 1999; 96: 2147-2152. (Pubitemid 29117882)
40. Jin P, Hardy S, Morgan DO. Nuclear localization of cyclin B1 controls mitotic entry after DNA damage. J Cell Biol 1998; 141: 875-885. (Pubitemid 28243956)
41. Toyoshima F, Moriguchi T, Wada A, Fukuda M, Nishida E. Nuclear export of cyclin B1 and its possible role in the DNA damage-induced G2 checkpoint. Embo J 1998; 17: 2728-2735. (Pubitemid 28227119)
42. Sato K, Sundaramoorthy E, Rajendra E, Hattori H, Jeyasekharan AD, Ayoub N et al. A DNA-damage selective role for BRCA1 E3 ligase in claspin ubiquitylation, CHK1 activation, and DNA repair. Curr Biol 2012; 22: 1659-1666.
43. Palacios J, Honrado E, Osorio A, Cazorla A, Sarrio D, Barroso A et al. Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers. Breast Cancer Res Treat 2005; 90: 5-14. (Pubitemid 40486996)
44. Morris JR, Boutell C, Keppler M, Densham R, Weekes D, Alamshah A et al. The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress. Nature 2009; 462: 886-890.
45. Reid LJ, Shakya R, Modi AP, Lokshin M, Cheng JT, Jasin M et al. E3 ligase activity of BRCA1 is not essential for mammalian cell viability or homology-directed repair of double-strand DNA breaks. Proc Natl Acad Sci USA 2008; 105: 20876-20881.
46. Shakya R, Reid LJ, Reczek CR, Cole F, Egli D, Lin CS et al. BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity. Science 2011; 334: 525-528.
47. Brodie SG, Deng CX. BRCA1-associated tumorigenesis: what have we learned from knockout mice? Trends Genet 2001; 17: S18-S22. (Pubitemid 32918307)
48. Xu X, Qiao W, Linke SP, Cao L, Li WM, Furth PA et al. Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis. Nat Genet 2001; 28: 266-271. (Pubitemid 32626030)
49. Wu W, Koike A, Takeshita T, Ohta T. The ubiquitin E3 ligase activity of BRCA1 and its biological functions. Cell Div 2008; 3: 1.
50. Ma Y, Fan S, Hu C, Meng Q, Fuqua SA, Pestell RG et al. BRCA1 regulates acetylation and ubiquitination of estrogen receptor-alpha. Mol Endocrinol 2010; 24: 76-90.
51. Lim KL, Chew KC, Tan JM, Wang C, Chung KK, Zhang Y et al. Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation. J Neurosci 2005; 25: 2002-2009. (Pubitemid 40289405)
52. Kirkpatrick DS, Hathaway NA, Hanna J, Elsasser S, Rush J, Finley D et al. Quantitative analysis of in vitro ubiquitinated cyclin B1 reveals complex chain topology. Nat Cell Biol 2006; 8: 700-710.
53. Yarden RI, Brody LC. BRCA1 interacts with components of the histone deacetylase complex. Proc Natl Acad Sci USA 1999; 96: 4983-4988. (Pubitemid 29214522)